Specialty Pharma Company Raising Funds In Guwahati

About Business

A DPIIT-recognized specialty pharmaceutical company established in 2023, focused on developing and marketing differentiated prescription-based formulations across orthopaedics, pain management, rheumatology, gastroenterology, and chronic care segments.

The company follows an asset-light business model by partnering with WHO-GMP-compliant third-party manufacturers for API sourcing and production while managing product development, branding, marketing, and distribution in-house. Currently, the business has successfully launched six pharmaceutical brands and sells its products through an established network of distributors and healthcare professionals.

Rather than competing in highly commoditized generic segments, the company focuses on specialty formulations with strong physician acceptance, improved bioavailability, and value-added therapeutic solutions. The business is now seeking growth capital to expand its sales network, introduce new products, strengthen working capital, and enter additional markets across India.

Clientele type

Orthopaedic surgeons
Rheumatologists
Pain management specialists
General physicians and internal medicine practitioners
Gastroenterologists
Hospitals, clinics, and nursing homes
Pharmaceutical distributors and stockists
Retail pharmacies and chemists

The company's products are prescribed by healthcare professionals and distributed through established pharmaceutical supply channels, ensuring broad patient access and sustainable market penetration. The business focuses on building long-term relationships with specialist physicians and key opinion leaders to drive prescription adoption and brand growth.

Premises

LEASED

Lease per month (in INR): 10.00 K

Security Deposit (in INR): 25.00 K

Carpet Area: 220 sq ft

The company operates from a leased office and administrative facility located in a commercial area of Guwahati, Assam. The premises serve as the company's headquarters for management, sales operations, marketing activities, warehousing coordination, and distributor engagement. The business follows an asset-light model utilizing WHO-GMP compliant third-party manufacturing partners, eliminating the need for significant investment in manufacturing infrastructure while enabling efficient scalability. Current infrastructure is adequate to support existing operations and planned near-term expansion. Additional office and warehousing capacity can be acquired as business requirements grow.

Asking Price Includes

The company is seeking ₹50 lakh in growth capital through equity and/or debt to support new product launches, strengthen working capital, expand the sales team, increase market penetration, procure inventory, and enter new geographic markets.

The business follows an asset-light model by leveraging third-party manufacturing partners and does not own any manufacturing facilities or real estate assets. Equity investors will be offered a minority stake, with terms to be finalized based on valuation and investment size. For debt funding, repayment terms and other commercial arrangements will be mutually agreed upon during the due diligence process.

Asking Price

INR 50.00 L

Minimum ticket size

INR 50.00 L

Reason

The company is raising growth capital to accelerate sales expansion, strengthen working capital, launch new products, and establish a stronger presence in additional markets across India

Licenses

FSSAI, DRUG LICENSE, TRADE LICENSE, GST

More Details

Management Team

The business is led by an experienced team with strong expertise across pharmaceutical product development, sales, operations, and supply chain management. The promoters possess hands-on industry experience in formulation development, physician engagement, distributor network expansion, and third-party manufacturing management, enabling the company to operate an efficient and scalable business model.

Key Achievements

Successfully launched six specialty pharmaceutical brands across high-growth therapeutic segments.
Built a growing network of specialist doctors, distributors, stockists, and pharmacy partners.
Established an asset-light and scalable operating model through WHO-GMP-compliant third-party manufacturing partnerships.
Developed a pipeline of differentiated formulations focused on orthopaedics, pain management, rheumatology, gastroenterology, and chronic care.
Achieved early commercial validation with steady revenue growth and an expanding market presence in the region.